Wei Ying Jen, MA (Oxon), BM BCh, M Med (Internal Medicine), MRCP (UK), FRCPath (UK, Haematology)
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Affiliate Faculty, Department of Clinical Cancer Genetics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | Royal College of Pathologists, GB, Haematolgy, Fellowship of the Royal College of Pathologists |
| 2015 | National University of Singapore, Singapore, SG, Internal Medicine, Master of Medicine |
| 2015 | University of Oxford, Oxford, Oxfordshire, GB, Master of Arts |
| 2015 | Royal College of Physicians, GB, Membership of the Royal College of Physicians |
| 2012 | University of Oxford, Oxford, Oxfordshire, GB, Bachelor of Medicine and Bachelor of Surgery |
| 2009 | University of Oxford, Oxford, Oxfordshire, GB, Medical Sciences, Bachelor of Arts |
Postgraduate Training
| 2023-2024 | Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Senior Resident, Haematology, National University Cancer Institute, Singapore, Singapore, Singapore |
| 2013-2016 | Resident, Internal Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, General Medicine, National University Hospital, Singapore, Singapore |
| 2013-2013 | House Officer, KK Women's & Children's Hospital, Singapore, Singapore |
| 2012-2013 | House Officer, Singapore General Hospital, Singapore, Singapore |
Licenses & Certifications
| 2025 | Texas Medical Board Physician License |
| 2025 | Texas Medical Board Faculty Temporary License |
| 2024 | Drug Enforcement Agency Controlled Substance Registration Certificate |
| 2024 | Texas Medical Board Faculty Temporary License |
| 2023 | Texas Physician-In-Training Permit |
| 2022 | Education Commission of Foreign Medical Graduates |
| 2019 | Certificate of Specialist Accreditation |
| 2016 | Singapore Medical Council Certificate of Medical Registration |
| 2016 | General Medical Council (UK) Registration |
Experience & Service
Faculty Academic Appointments
Adjunct Assistant Professor, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2023 - 2024
Senior Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2019 - 2023
Clinical Lecturer, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2017 - 2019
Administrative Appointments/Responsibilities
Undergraduate Division Director, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2022 - 2024
System Block Lead, Department of Medicine, National University of Singapore Yong Loo Lin School of Medicine, Singapore, Singapore, 2021 - 2023
Intramural Institutional Committee Activities
Member, Telemedicine Committee, National University Health System, 2020 - 2024
Member, NUHS App Workgroup, National University Health System, 2020 - 2024
Member, NCIS Right Siting Workgroup, National University Cancer Institute, Singapore, 2019 - 2024
Member, NCIS Annual Research Meeting Scientific Committee, National University Cancer Institute, Singapore, 2018 - 2020
Member, Resident's Research Committee, National University Health System, 2018 - 2019
Member, Residents' Welfare Committee, National University Health System, 2015 - 2016
Extramural Institutional Committee Activities
Member, Cullinan Scientific Review Committee, Cullinan Oncology, 2026 - Present
Member, Sumitomo Scientific Review Committee, Sumitomo Dainippon Pharma (United States), 2026 - Present
Committee Member, iwAL Scientific Committee, Video Journal of Hematological Oncology, 2026
Member, Cogent Systemic Mastocytosis Scientific Advisory Board, MD Education, 2026 - Present
Member, MD Anderson Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Key Opinion Leader, Singapore Translational Cancer Consortium, Singapore Translational Cancer Consortium, 2022 - Present
Member, Asia-Pacific Leukaemia Consortium, Asia-Pacific Leukaemia Consortium, 2022 - Present
Chairperson, Institutional Review Board, Nanyang Girls' High School, 2017 - 2019
Honors & Awards
| 2024 | EHA Educational Travel Grant, European Hematology Association |
| 2024 | Conquer Cancer – Eisai Inc. Endowed Merit Award, American Society of Clinical Oncology |
| 2023 | NCIS SHINE Incredible Care Award, Nominated by peers, allied health and supervisors to recognise staff who have contributed significantly to the institution and positively influenced their teams |
| 2022 | The Public Administration Medal (Bronze) (COVID-19), Prime Minister's Office, Singapore |
| 2022 | NCIS SHINE Incredible People Award, National University Cancer Institute, Singapore |
| 2020 | Quality Improvement Project Merit Award, National University Hospital |
| 2020 | Best Trainee Award, Chapter of Haematologists, College of Physicians, Academy of Medicine, Singapore |
| 2017 | Best Senior Resident Tutor Award, University Medicine Cluster, National University Hospital |
| 2016 | Junior Doctor Teaching Award, National University of Singapore Yong Loo Lin School of Medicine |
| 2014 | Best Poster Award, World Congress of Internal Medicine |
| 2012 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2011 | Wellcome Trust Student Elective Prize, Wellcome Trust |
| 2010 | Glaxo Scholarship, St Catherine's College, University of Oxford |
| 2010 | Light Senior Scholarship, St Catherine's College, University of Oxford |
| 2009 | St Catherine's College Book Prize, St Catherine's College, University of Oxford |
| 2009 | Gibbs Prize, Pre-Clinical Faculty Office, University of Oxford |
| 2008 | College Exhibition, St Catherine's College, University of Oxford |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2026. Outcomes and natural history of telomere biology disorders in patients without a concurrent hematological disorder. Conference. Genetic Basis of Blood Cancers and Bone Marrow Failure. Niagra Falls, New York, US.
- 2025. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Conference. American Society of Hematology. Orlando, Florida, US.
International Presentations
- 2026. Updates in Acute Myeloid Leukemia. Invited. Singapore, SG.
- 2026. KMT2A-PTD in AML. Invited. 5th Translational Summit on Hematologic Malignancies, BM.
- 2026. Tagraxofusp, a first-in-class CD123-targeted agent, five years after its approval for BPDCN. Invited. 5th Translational Summit on Hematologic Malignancies, BM.
- 2026. Outcome of second-line therapy in adult b-cell Philadelphia chromosome positive acute lymphoblastic leukemia. Conference. European Hematology Association Annual Congress. Stockholm, SE.
- 2026. Outcome of second-line therapy in adult b-cell Philadelphia chromosome positive acute lymphoblastic leukemia. Conference. European Hematology Association Annual Congress. Stockholm, SE.
- 2025. Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapy. Panelist.
- 2025. Outcomes of the acute myeloid leukemia-defining MECOM rearrangement differ based on blast count at diagnosis. Conference. European Hematology Association Annual Congress. Milan, IT.
- 2025. Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapy. Conference. European Hematology Association Annual Congress. Milan, IT.
- 2024. FLAG-IDA + venetoclax (VEN) in newly diagnosed (ND) or relapsed / refractory (RR) AML. Conference. European Hematology Association Annual Congress. Madrid, ES.
Patient Reviews
CV information above last modified November 11, 2026